secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001372514-24-000007
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties
--------------------------------------------------------------------------------

- $16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.
- TOI gets exclusive worldwide rights (ex-Asia) for retinitis pigmentosa and other ophthalmic uses.
- Kiora responsible for Phase 2 design; TOI for Phase 3 and commercialization.
- Phase 1/2 ABACUS data showed meaningful vision improvements; Phase 2 starts early 2024.
- Investor webcast scheduled for Jan 31, 2024 at 5:30 pm ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/0001372514-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/kprx-20240125.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer